Annual Cash & Cash Equivalents:
$358.48M+$7.99M(+2.28%)Summary
- As of today, AUPH annual cash & cash equivalents is $358.48 million, with the most recent change of +$7.99 million (+2.28%) on December 31, 2024.
- During the last 3 years, AUPH annual cash & cash equivalents has fallen by -$107.60 million (-23.09%).
- AUPH annual cash & cash equivalents is now -23.09% below its all-time high of $466.08 million, reached on December 31, 2021.
Performance
AUPH Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$351.81M+$36.67M(+11.64%)Summary
- As of today, AUPH quarterly cash & cash equivalents is $351.81 million, with the most recent change of +$36.67 million (+11.64%) on September 30, 2025.
- Over the past year, AUPH quarterly cash & cash equivalents has increased by +$3.06 million (+0.88%).
- AUPH quarterly cash & cash equivalents is now -24.52% below its all-time high of $466.08 million, reached on December 31, 2021.
Performance
AUPH Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AUPH Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +2.3% | +0.9% |
| 3Y3 Years | -23.1% | -6.6% |
| 5Y5 Years | +17.1% | -10.3% |
AUPH Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -23.1% | +2.3% | -9.7% | +12.4% |
| 5Y | 5-Year | -23.1% | +17.1% | -24.5% | +22.8% |
| All-Time | All-Time | -23.1% | >+9999.0% | -24.5% | >+9999.0% |
AUPH Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $351.81M(+11.6%) |
| Jun 2025 | - | $315.13M(+0.7%) |
| Mar 2025 | - | $312.90M(-12.7%) |
| Dec 2024 | $358.48M(+2.3%) | $358.48M(+2.8%) |
| Sep 2024 | - | $348.75M(+5.5%) |
| Jun 2024 | - | $330.48M(+3.3%) |
| Mar 2024 | - | $319.91M(-8.7%) |
| Dec 2023 | $350.49M(-10.0%) | $350.49M(+3.7%) |
| Sep 2023 | - | $337.90M(-3.7%) |
| Jun 2023 | - | $350.71M(-3.0%) |
| Mar 2023 | - | $361.53M(-7.2%) |
| Dec 2022 | $389.39M(-16.5%) | $389.39M(+3.4%) |
| Sep 2022 | - | $376.64M(-3.9%) |
| Jun 2022 | - | $391.74M(-6.5%) |
| Mar 2022 | - | $418.75M(-10.2%) |
| Dec 2021 | $466.08M(+17.0%) | $466.08M(+62.7%) |
| Sep 2021 | - | $286.40M(-10.1%) |
| Jun 2021 | - | $318.74M(-8.5%) |
| Mar 2021 | - | $348.26M(-12.6%) |
| Dec 2020 | $398.33M(+30.2%) | $398.33M(+1.6%) |
| Sep 2020 | - | $392.04M(+48.3%) |
| Jun 2020 | - | $264.35M(-7.6%) |
| Mar 2020 | - | $286.12M(-6.5%) |
| Dec 2019 | $306.02M(+143.2%) | $306.02M(+127.5%) |
| Sep 2019 | - | $134.54M(+2.3%) |
| Jun 2019 | - | $131.49M(-8.9%) |
| Mar 2019 | - | $144.33M(+14.7%) |
| Dec 2018 | $125.86M(-27.4%) | $125.86M(-9.4%) |
| Sep 2018 | - | $138.88M(-7.5%) |
| Jun 2018 | - | $150.20M(-5.6%) |
| Mar 2018 | - | $159.13M(-8.3%) |
| Dec 2017 | $173.46M(+337.5%) | $173.46M(-4.9%) |
| Sep 2017 | - | $182.41M(-3.9%) |
| Jun 2017 | - | $189.79M(-6.1%) |
| Mar 2017 | - | $202.12M(+409.8%) |
| Dec 2016 | $39.65M(+151.7%) | $39.65M(+157.8%) |
| Sep 2016 | - | $15.38M(+26.9%) |
| Jun 2016 | - | $12.12M(+15.1%) |
| Mar 2016 | - | $10.53M(-33.1%) |
| Dec 2015 | $15.75M(-51.8%) | $15.75M(-23.5%) |
| Sep 2015 | - | $20.58M(-20.0%) |
| Jun 2015 | - | $25.74M(-11.4%) |
| Mar 2015 | - | $29.04M(-11.2%) |
| Dec 2014 | $32.70M(+1695.9%) | $32.70M(-7.9%) |
| Sep 2014 | - | $35.53M(-9.1%) |
| Jun 2014 | - | $39.09M(-9.7%) |
| Mar 2014 | - | $43.29M(+2277.2%) |
| Dec 2013 | $1.82M(+885.4%) | $1.82M(-59.7%) |
| Sep 2013 | - | $4.52M(+897.1%) |
| Jun 2013 | - | $453.10K(+1252.5%) |
| Mar 2013 | - | $33.50K(-81.9%) |
| Dec 2012 | $184.80K | $184.80K(-36.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2012 | - | $288.60K(-78.6%) |
| Jun 2012 | - | $1.35M(-67.9%) |
| Mar 2012 | - | $4.19M(-46.7%) |
| Dec 2011 | $7.86M(+23.1%) | $7.86M(+7.7%) |
| Sep 2011 | - | $7.30M(-15.8%) |
| Jun 2011 | - | $8.67M(-14.7%) |
| Mar 2011 | - | $10.16M(+59.1%) |
| Dec 2010 | $6.39M(+39.6%) | $6.39M(-9.3%) |
| Sep 2010 | - | $7.04M(+78.4%) |
| Jun 2010 | - | $3.95M(-22.5%) |
| Mar 2010 | - | $5.09M(+11.3%) |
| Dec 2009 | $4.58M(-78.0%) | $4.58M(-21.4%) |
| Sep 2009 | - | $5.82M(-7.7%) |
| Jun 2009 | - | $6.31M(-23.0%) |
| Mar 2009 | - | $8.20M(-60.6%) |
| Dec 2008 | $20.82M(-35.8%) | $20.82M(-21.1%) |
| Sep 2008 | - | $26.38M(-11.7%) |
| Jun 2008 | - | $29.88M(+43.2%) |
| Mar 2008 | - | $20.87M(-35.7%) |
| Dec 2007 | $32.45M(+46.7%) | $32.45M(-17.1%) |
| Sep 2007 | - | $39.15M(-13.4%) |
| Jun 2007 | - | $45.19M(-6.1%) |
| Mar 2007 | - | $48.13M(+117.5%) |
| Dec 2006 | $22.13M(-51.1%) | $22.13M(-25.2%) |
| Sep 2006 | - | $29.60M(-15.6%) |
| Jun 2006 | - | $35.05M(-9.0%) |
| Mar 2006 | - | $38.50M(-14.9%) |
| Dec 2005 | $45.22M(-10.0%) | $45.22M(-11.9%) |
| Sep 2005 | - | $51.30M(+40.3%) |
| Jun 2005 | - | $36.57M(-14.9%) |
| Mar 2005 | - | $43.00M(-14.4%) |
| Dec 2004 | $50.25M(-20.3%) | $50.25M(-7.0%) |
| Sep 2004 | - | $54.03M(+1.2%) |
| Jun 2004 | - | $53.39M(-9.6%) |
| Mar 2004 | - | $59.04M(-6.4%) |
| Dec 2003 | $63.07M(+55.2%) | $63.07M(-3.5%) |
| Sep 2003 | - | $65.35M(+18.1%) |
| Jun 2003 | - | $55.32M(+41.0%) |
| Mar 2003 | - | $39.23M(-3.5%) |
| Dec 2002 | $40.64M(+21.8%) | $40.64M(-9.4%) |
| Sep 2002 | - | $44.87M(+1.4%) |
| Jun 2002 | - | $44.23M(+33.9%) |
| Mar 2002 | - | $33.03M(-1.0%) |
| Dec 2001 | $33.37M(+176.9%) | - |
| Dec 2001 | - | $33.37M(+25.9%) |
| Sep 2001 | - | $26.50M(+212.4%) |
| Jun 2001 | - | $8.48M(-8.6%) |
| Mar 2001 | - | $9.28M(+6449.8%) |
| Dec 2000 | $12.05M(+372.4%) | - |
| Nov 1999 | $2.55M | - |
| Aug 1999 | - | $141.70K(-87.3%) |
| May 1999 | - | $1.12M(-6.4%) |
| Feb 1999 | - | $1.19M |
FAQ
- What is Aurinia Pharmaceuticals Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Aurinia Pharmaceuticals Inc.?
- What is Aurinia Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
- What is Aurinia Pharmaceuticals Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Aurinia Pharmaceuticals Inc.?
- What is Aurinia Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
What is Aurinia Pharmaceuticals Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of AUPH is $358.48M
What is the all-time high annual cash & cash equivalents for Aurinia Pharmaceuticals Inc.?
Aurinia Pharmaceuticals Inc. all-time high annual cash & cash equivalents is $466.08M
What is Aurinia Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
Over the past year, AUPH annual cash & cash equivalents has changed by +$7.99M (+2.28%)
What is Aurinia Pharmaceuticals Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AUPH is $351.81M
What is the all-time high quarterly cash & cash equivalents for Aurinia Pharmaceuticals Inc.?
Aurinia Pharmaceuticals Inc. all-time high quarterly cash & cash equivalents is $466.08M
What is Aurinia Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, AUPH quarterly cash & cash equivalents has changed by +$3.06M (+0.88%)